Form 4: AIM ImmunoTech Director Nancy Bryan Acquires Shares in Lieu of Compensation

Sentiment:

SEC Form 4


Director Nancy Bryan acquired 43,330 shares of AIM ImmunoTech Inc. common stock on February 14, 2025, in lieu of director compensation.

Summary

  • On February 14, 2025, Nancy Bryan, a director of AIM ImmunoTech Inc., acquired 43,330 shares of common stock.
  • The shares were acquired at a price of $0.1202 per share.
  • This acquisition was made in lieu of director compensation, as part of the issuer's Cash Conservation Plan.
  • Following the transaction, Bryan directly owns 208,403 shares of AIM ImmunoTech Inc.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard transaction of a director receiving shares in lieu of compensation. The Cash Conservation Plan suggests the company is managing its finances carefully.

Positives

  • The director's acceptance of shares in lieu of cash compensation demonstrates confidence in the company's future.

Industry Context

Directors sometimes take shares in lieu of cash, especially in smaller companies, to conserve cash. This is a common practice.

Stakeholder Impact

  • The acceptance of shares in lieu of cash compensation by a director could be viewed positively by shareholders as it aligns the director's interests with the company's and helps conserve cash.

Key Dates

DateDescription
02/14/2025Date of transaction: Nancy Bryan acquired 43,330 shares of AIM ImmunoTech Inc.
02/18/2025Date of signature on the Form 4 filing.

Keywords

AIM ImmunoTech Inc., Nancy Bryan, director, share acquisition, common stock, Form 4, Cash Conservation Plan, compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.